AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 3 - (NewsRx.com & NewsRx.net) --
BTG (BGC), a technology commercialization company, has acquired Bilosomes, a new oral vaccine delivery vesicle that protects antigens from the digestive process and can also act as an immunological adjuvant. BTG is now seeking to license this technology and develop it further.
Bilosomes include bile salts in their formulation, which stabilize the vesicle preparation and prevent premature release of the antigen. Bilosomes deliver the antigen directly into the mucosal tissue and as a result:
* Smaller quantities of antigens are required to be effective
* Both cellular and humoral immune responses can be induced
* A wider range of antigens, including smaller and generally weaker antigens, could be delivered
...
Source: HighBeam Research, BTG Acquires Oral Vaccine Delivery Technology.(Brief Article)